ELAN News & Events

Elanco Animal Health plans to establish Elanco Ventures, a dedicated corporate venture capital platform designed to support, invest and advance innovation in animal health. To be backed by a $25M multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector. While primarily focused on animal health, the fund may also explore opportunities within the broader One Health landscape. Launching in late 2026, Elanco Ventures will be overseen by Eric Steager and focus on early-stage companies, prioritizing Pre-Seed, Seed and Series A stages of development.

Elanco Animal Health announced the U.S. Department of Agriculture approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1/2 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis, two increasingly prevalent threats to canine health. As an expansion of the TruCan Ultra line, this new 1/2 mL formulation provides the same broad protection as the category-exclusive 1 mL version but in half the volume. This combination formulation allows veterinarians to provide essential protection without the need for multiple injections. TruCan Ultra Lyme-L4 is expected to begin shipping in the next 30 days.

Elanco announced the phased launch of Befrena - tirnovetmab -, a new anti-IL-31 monoclonal antibody injection for treatment of canine allergic and atopic dermatitis. Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours. Befrena is claimed to offer at least 6 to 8 weeks of itch relief, in contrast to the 4 to 8 weeks of the current market incumbent, lokivetmab, and to start controlling itch within 24 hours. Elanco received approval of Befrena from the USDA in December 2025.